In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer

被引:90
作者
Miller, RA
Woodburn, K
Fan, Q
Renschler, MF
Sessler, JL
Koutcher, JA
机构
[1] Univ Texas, Dept Chem & Biochem, Austin, TX USA
[2] Pharmacyclics Inc, Sunnyvale, CA 94086 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 45卷 / 04期
关键词
gadolinium; texaphyrin; radiation; sensitizer; preclinical;
D O I
10.1016/S0360-3016(99)00274-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Gadolinium texaphyrin (Gd-Tex, PCI-0120) is an expanded porphyrin that has demonstrated radiation enhancement. In this study, we evaluated the radiation enhancement and biolocalization of Gd-Tex in three animal tumor models. Methods and Materials: EMT6, SMT-F, and MCa tumors were established intramuscularly or subcutaneously, Gd-Tex and other metallotexaphyrins were administered prior to single or multiple fractions of radiation. C-14-labeled Gd-Tex was used for biolocalization studies. Results: Gd-Tex, in combination with radiation, produced significant tumor growth delay compared to irradiated control groups in both single and multifraction radiation studies. Gd-Tex radiation enhancement was observed only when the drug was given before, but not after irradiation. Several metallotexaphyrins, identical except for the metal ion, were studied in the EMT6 tumor model including gadolinium (Gd), lutetium (Lu), europium (Eu), yttrium (Y), and cadmium (Cd) texaphyrin complexes. Only Gd-Tex produced radiation enhancement. Biodistribution studies using C-14-labeled Gd-Tex demonstrated drug selectivity and retention in tumors growing intramuscularly compared to uninvolved muscle and plasma. Conclusions: Gd-Tex produces reproducible radiation enhancement in a variety of in vivo tumor models. This drug's unique radiochemistry, tumor selectivity, and in vivo activity suggests possible mechanisms of action not addressed by in vitro assay methods. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:981 / 989
页数:9
相关论文
共 38 条
[1]   RESPONSE OF XENOGRAFTS OF HUMAN-MALIGNANT GLIOMAS AND SQUAMOUS-CELL CARCINOMAS TO FRACTIONATED-IRRADIATION [J].
BAUMANN, M ;
DUBOIS, W ;
PU, A ;
FREEMAN, J ;
SUIT, HD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (04) :803-809
[2]   COMPARISON BETWEEN INVITRO RADIOSENSITIVITY AND INVIVO RADIORESPONSE OF MURINE TUMOR-CELL LINES .1. PARAMETERS OF INVITRO RADIOSENSITIVITY AND ENDOGENOUS CELLULAR GLUTATHIONE LEVELS [J].
BRISTOW, RG ;
HARDY, PA ;
HILL, RP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (01) :133-145
[3]   COMPARISON BETWEEN INVITRO RADIOSENSITIVITY AND INVIVO RADIORESPONSE IN MURINE TUMOR-CELL LINES .2. INVIVO RADIORESPONSE FOLLOWING FRACTIONATED TREATMENT AND INVITRO INVIVO CORRELATIONS [J].
BRISTOW, RG ;
HILL, RP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (02) :331-345
[4]   SR-4233 (TIRAPAZAMINE) - A NEW ANTICANCER DRUG EXPLOITING HYPOXIA IN SOLID TUMORS [J].
BROWN, JM .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1163-1170
[5]   RADIOSENSITIZATION OF HYPOXIC CELLS INVIVO BY SR-2508 AT LOW RADIATION-DOSES - A PRELIMINARY-REPORT [J].
BROWN, JM ;
YU, NY .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (08) :1207-1212
[6]  
CARDE P, 1998, P AN M AM SOC CLIN, V17, pA379
[7]  
Coleman CN, 1999, J CLIN ONCOL, V17, P1
[8]  
COLEMAN CN, 1996, CANC CHEMOTHERAPY BI, P553
[9]  
FINGAR VH, 1998, PHOTOCHEM PHOTOBIO S, V67, pS25
[10]  
James B R, 1996, Met Based Drugs, V3, P85, DOI 10.1155/MBD.1996.85